Clinical trials: multiple sclerosis
Secondary Progressive Multiple Sclerosis
A Study for Patients With Secondary Progressive Multiple Sclerosis
The purpose of this study is to determine whether MBP8298 is effective and safe in the treatment secondary progressive multiple sclerosis. Dirucotide is generic name for MBP8298.
- Trial name
- MAESTRO-01 (NCT00869726)
- Testing
- dirucotide
- Where
- 10 sites in Canada, Denmark and 8 more
- Volunteers
- 596 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.
This study will compare the effect of A4I antagonist and placebo on MRI lesions,on clinical endpoints, and safety in patients with relapsing Multiple Sclerosis (MS).
- Trial name
- NCT00104143
- Testing
- A4I Antagonist
- Where
- 39 sites in Bulgaria, Canada and 7 more
- Sponsor
- Hoffmann-La Roche
Fatigue, Multiple Sclerosis
Biofeedback-based Relaxation Training or Self-alert Training to Alleviate Fatigue in Multiple Sclerosis Patients.
The presented study compares the effectiveness of a biofeedback-based relaxation training with the effectiveness of a biofeedback-based self-alert training on the reduction of fatigue in multiple sclerosis patients using a…
- Trial name
- NCT03268187
- Testing
- Biofeedback, Self-Alert Training, Relaxation Training
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Rehazentrum Wilhelmshaven
Relapsing Multiple Sclerosis
Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab
The study provided efficacy, safety, and pharmacokinetics (PK) data for patients with relapsing multiple sclerosis (RMS) in Japan and the other countries
- Trial name
- NCT03249714
- Testing
- Ofatumumab
- Where
- 14 sites in Japan, Russia
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control
The purpose of the study is to research the association between receiving Tysabri® (natalizumab), interferon beta-1a, glatiramer acetate or not having any treatment for your MS and how it may or may not impact certain white blood…
- Trial name
- NCT01626248
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- John F. Foley, MD
Multiple Sclerosis
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.
- Trial name
- CogniPlus (NCT01491100)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 17 sites in Albania, Algeria and 15 more
- Volunteers
- 1,085 people
- Sponsor
- Bayer
Multiple Sclerosis, Gait Disorders, Neurologic
TRAIN-BW: Backward Walking Training in Multiple Sclerosis
Individuals with multiple sclerosis (MS) experience in impairments in mobility and cognition that increase the risk for accidental falls. More than 50% of individuals with MS experience injurious falls within a 6-month period.
- Conditions
- Multiple Sclerosis, Gait Disorders, Neurologic, Accidental Fall
- Trial name
- TRAIN-BW (NCT04091464)
- Testing
- Backward Walking Training, Forward Walking Training
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Wayne State University
Multiple Sclerosis
A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years
This is an observational, non comparative, non-randomised, open-label, retrospective, single centre study planned to collect the data of subjects diagnosed with multiple sclerosis (MS) as per Poser or McDonald criteria between…
- Trial name
- NCT01084798
- Where
- Taiwan
- Volunteers
- 123 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute…
- Trial name
- NCT00349193
- Testing
- laquinimod 0.3, laquinimod 0.6
- Volunteers
- 306 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Chewing Under Dual-Tasking in MS
This study aims to investigate the effects of visual, auditory, and motor dual-task conditions on chewing performance in individuals with multiple sclerosis, compared with healthy controls.
- Trial name
- NCT07366216
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ondokuz Mayıs University
Multiple Sclerosis
American Ginseng Treatment for Multiple Sclerosis Related Fatigue
This research project will determine the safety and tolerability of ginseng in subjects with MS and will gather preliminary data on the efficacy of ginseng vs placebo for the treatment of MS fatigue.
- Trial name
- NCT00754832
- Testing
- American ginseng extract HT-1001
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Oregon Health and Science University
Migraine Disorders, Pain
The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.
Migraine is a frequent and debilitating neurologic disorder. It is more frequent in women, and more prevalent in patients with autoimmune and/or inflammatory diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA)…
- Conditions
- Migraine Disorders, Pain, Autoimmune Diseases, Multiple Sclerosis
- Trial name
- SIIM (NCT06426316)
- Testing
- Blood test
- Where
- France
- Volunteers
- 396 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Amyotrophic Lateral Sclerosis, ALS
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Phase 1, open-label study of BHV-0223 in ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03520517
- Testing
- BHV-0223
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Multiple Sclerosis, MS, Multiple Sclerosis
Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory and disabling disease of the Cnetral Nervous System characterized by relapsing and / or progressive somatosensory, motor and vestibular clinical manifestations.
- Conditions
- Multiple Sclerosis, MS, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- NCT07680738
- Testing
- Transcranial Direct Current Stimulation
- Where
- Mexico
- Volunteers
- 38 people
- Sponsor
- Universidad de Almeria
Multiple Sclerosis
Effects of Resistance Training in Multiple Sclerosis: a Randomized Trial.
This is a longitudinal study to examine the effects of a short-term training program on neurofilamet and GFAP plasma levels. Participants will be divided in two groups: control group (moderate aerobic training) and active group…
- Trial name
- ACTIVE (NCT06478784)
- Testing
- Resistance training, Low aerobic training
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Clínico Universitario de Valladolid
Multiple Sclerosis
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
- Trial name
- SUNBEAM (NCT02294058)
- Testing
- Ozanimod, Interferon beta-1a
- Where
- 224 sites in United States, Belarus and 23 more
- Volunteers
- 1,346 people
- Sponsor
- Celgene
Multiple Sclerosis
Profile of Adherence to Therapy and Interventions to Promote Adherence in MS
Adherence is an active process wherein the patient acts in collaboration with the medical and paramedical staff in order to improve his/her health.
- Trial name
- NCT02488343
- Testing
- Behavioral Intervention
- Where
- Israel
- Volunteers
- 400 people
- Sponsor
- Carmel Medical Center
Multiple Sclerosis (MS)
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to determine if a sequential combination therapy of natalizumab and alemtuzumab induces peripheral tolerance and reduces the annualized relapse rate (ARR) in patients with relapsing-remitting multiple…
- Trial name
- SUPPRESS (NCT03135249)
- Testing
- Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis, Insulin Resistance
Insulin Resistance in Egyptian Patients With Multiple Sclerosis
The goal of this three-phase interventional study is to determine the prevalence of Insulin resistance in non-diabetic patients with multiple sclerosis in Egypt The main questions it aims to answer are: 1.
- Trial name
- IR-MS (NCT06017726)
- Testing
- treatment of insulin resistance with appropriate modality according to each patient
- Volunteers
- 100 people
- Sponsor
- Assiut University
Progressive Multiple Sclerosis
Telerehabilitation in Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a highly disabling chronic, inflammatory, demyelinating disease of the Central Nervous System (CNS). Significant progress has been made during the past three decades in managing the relapsing-remitting…
- Trial name
- NCT06485115
- Testing
- Digital Telerehabilitation (Euleria Home), Conventional therapy
- Where
- Italy
- Volunteers
- 78 people
- Sponsor
- Universita di Verona
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.